Xcout IntelSign inSubscribe

NIOX GROUP PLC

NIOXMedical DevicesOxford, United Kingdom

NIOX Group Plc is a worldwide company dedicated to innovating, developing, and distributing medical devices that measure fractional exhaled nitric oxide (FeNO). A key product is the NIOX VERO system, an easily portable and non-invasive diagnostic tool designed for immediate, on-site patient use. This system includes a compact device alongside a suite of disposable items like sensors, individual mouthpieces, and breathing handles, all essential for quantifying FeNO levels in patients. The company, which was founded in 2006 and is headquartered in Oxford, United Kingdom, was formerly known as Circassia Group Plc until its renaming to NIOX Group Plc in September 2022.

Subscribe to see NIOX GROUP PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

NIOX GROUP PLC at a glance

NIOX GROUP PLC is a medical devices company headquartered in Oxford, United Kingdom, founded in 2006. It is publicly listed (NIOX) with a market capitalisation of $384.1M.

Industry
Medical Devices
Headquarters
Oxford, United Kingdom
Market cap
$384.1M
Employees
97
Ticker
NIOX
Founded
2006

NIOX GROUP PLC competitors

A few of NIOX GROUP PLC's closest competitors — see the full list of competitors and alternatives →

ANGLE plcMedical DevicesGuildford, United States
66% match

CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.

Valuation—
Employees—
ANGLE plc competitors & alternatives →

Get NIOX GROUP PLC's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

NIOX GROUP PLC — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on NIOX GROUP PLC in Xcout Intel

  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →